Ng George K purchased $6K of PCSA

Processa Pharmaceuticals (Nasdaq: PCSA) completed a July 2026 acquisition of Vidya Therapeutics, adding CNS-penetrant BTK inhibitor VT-7208 and shifting focus to immune-mediated diseases. Vidya holders received about 46% and private placement investors about 52.6%, leaving prior Processa holders about 0.9%. A $200M private placement funds operations into 2H 2029; Phase II starts planned in 2H 2026 (food allergy, CSU) and 1H 2027 (RMS).

The healthcare sector saw multiple company-specific moves. Pfizer and BioNTech received EU approval for an updated COVID-19 vaccine targeting the XFG variant. Cipla won FDA approval for generic Advair Diskus, and Viatris gained FDA approval for its Gwyn Lo contraceptive patch. AbbVie’s Rinvoq was approved in the EU for non-segmental vitiligo. Boston Scientific announced an $800M restructuring plan, while GSK launched a $2.5B cost-saving program. J&J and Sail agreed a $3.51B CAR-T deal; Argenx ac

Processa Pharmaceuticals, Inc. (PCSA), a clinical-stage biotechnology company, has acquired privately held Vidya Therapeutics, Inc. and simultaneously raise approximately $200 million through a private financing. Vidya's lead candidate, VT-7208, is a next-generation CNS-penetrant Bruton's tyrosine kinase inhibitor (BTKi) being developed for immune-mediated diseases like food allergy, chronic spontaneous urticaria (CSU), and relapsing multiple sclerosis (RMS).

The acquisition transforms Processa's pipeline with the addition of clinical-stage BTK inhibitor VT-7208, while a concurrent $200 million private placement is expected to fund development into 2029. Key Investor Takeaways Processa Pharmaceuticals (NASDAQ:PRCT) acquired Vidya Therapeutics, adding clinical-stage BTK inhibitor VT-7208 to its pipeline. The company simultaneously secured a private placement expected to raise approximately $200 million to fund multiple Phase 2 clinical programs.

Processa Pharmaceuticals (PCSA) will acquire privately held Vidya Therapeutics and raise about $200M via a private financing. Vidya’s lead candidate VT-7208 is a CNS-penetrant BTK inhibitor for food allergy, CSU, and RMS. Deal terms include 558,398 PCSA shares plus preferred shares; financing priced at $1,221.19/share. Expected close July 30, 2026; PCSA stock fell 38% to $1.88.

Processa Pharmaceuticals, Inc. (PCSA) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-2.1 2 ex2-1.htm EX-2.1 Exhibit 2.1 CONFIDENTIAL Execution Version AGREEMENT AND PLAN OF MERGER by and among: PROCESSA PHARMACEUTICALS , INC. , a Delaware corporation; VENUS MERGER SUB I, INC. , a Delaware corporation; VENUS MERGER SUB II, LLC , a Delaware limited liability com